High-grade serous ovarian cancer (HGSOC) has a high mortality rate because the disease is asymptomatic in early stages and is resistant to treatments. A novel modality for diagnosis in the early stages of carcinogenesis is needed. In this issue of *EBioMedicine*, Hellner et al. present novel genetic aspects of small lesions of HGSOC ([@bb0020]). They performed screening by LFR WGS technology for small HGSOC lesions from a patient who underwent treatment and found 750 genomic mutations. Gene ontology analysis revealed that the gene mutations are related to stem cell differentiation, and the authors finally found 6 novel non-coding mutations (*BB1* - *BB6*) in proximity of *sex determining region Y-box2* (*SOX2*), a key driver of stem cell differentiation ([@bb0035]). Deep genetic analysis revealed that the *BB5* region is commonly mutated in HGSOC tissues. A reporter assay and genome engineering using CRISPR/Cas9 system revealed that the *BB5* region is a novel repressor of the *SOX2* gene and that mutation in the *BB5* region induces protein expression of SOX2. Mutations in the *BB5* region were detected in non-neoplastic fallopian tube epithelium (FTE) of HGSOC cases and also in normal FTE of *BRCA1* or *BRCA2* mutation carriers who are at high risk for HGSOC. Surprisingly, immunohistochemical analysis of *BB5* mutation carriers revealed that SOX2 protein is broadly expressed in even normal FTEs, indicating that non-neoplastic FTEs with *BB5* mutation propagated clonally. SOX2 protein is expressed in earlier stages than TP53 protein expression indicating overexpression of SOX2 protein is earlier event than *TP53* gene mutation. Interestingly, SOX2 protein expression decreased after the establishment of an ovarian cancer lesion. These results suggest that mutation in the *SOX2 BB5* region is an early carcinogenesis driver mutation in HGSOCs and that detection of SOX2 protein is a promising biological marker for prediction of HGSOC.

In mouse models, stem cells in the ovary and tubal epithelia were identified as Lgr5-positive cells ([@bb0015], [@bb0030]), and Lgr5-positive epithelial stem cells are prone for genetically engineered ovarian cancer. Since Lgr5 is induced by Wnt/β-Catenin signaling, Wnt/β-Catenin signaling in epithelial stem cells seems to be activated ([@bb0010]). SOX2 is also induced by Wnt/β-Catenin signaling, indicating that epithelial stem cells that are sensitive for ovarian carcinogenesis are positive for SOX2. However, a recent study revealed that SOX2 protein is induced by mechanisms other than activation of Wnt/β-Catenin signaling ([@bb0020]).

SOX2 protein expression was found to be decreased in HGSOC tissues in this study. On the other hand, SOX2 is overexpressed in ovarian cancer stem cells (CSCs) ([@bb0005], [@bb0025]), and SOX2 expression is essential for tumorigenicity of ovarian CSCs. Therefore, detection of SOX2 protein *in vivo* is important not only for early detection of high-risk FTEs but also for prediction of the outcome in advanced HGSOC cases. Finally, SOX2 protein might have two functional roles in the development of HGSOCs: (I) SOX2 protein is expressed in normal FTEs with *BB5* mutation and may have a role in clonal propagation *in situ*, and SOX2-positive FTEs are prone for HGSOCs and (II) after generation of an HGSOC lesion, SOX2 protein is expressed in a small subpopulation of HGSOC cancer stem cells. SOX2 is a transcription factor and further analysis of SOX2 target genes both in normal FTEs and cancer stem cells reveal the different functions of SOX2 protein in both cells.
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